Literature DB >> 12606501

Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs.

Stephan Schiekofer1, Martin Andrassy, Jiang Chen, Gottfried Rudofsky, Jochen Schneider, Thoralf Wendt, Norbert Stefan, Per Humpert, Andreas Fritsche, Michael Stumvoll, Erwin Schleicher, Hans-Ulrich Häring, Peter P Nawroth, Angelika Bierhaus.   

Abstract

Twenty-three nondiabetic volunteers were divided into three groups. In group A (n = 9), the glucose infusion was adjusted to maintain blood glucose at 5 mmol/l (euglycemic clamp). In group B (n = 9), the glucose infusion was adjusted to maintain blood glucose at 10 mmol/l (hyperglycemic clamp) over 2 h. Group C consisted of five volunteers who were studied as the control group. Peripheral blood mononuclear cells (PBMCs) were isolated before and at the end of a 2-h clamp. In group C, PBMCs were isolated before and after 2 h without performing a clamp. The euglycemic clamp as well as "no clamp" had no effects on all parameters studied. In contrast, a significant increase in carboxymethyllysine (CML) content and p21(ras) and p42/44 mitogen-activated protein kinase (MAPK) phosphorylation was observed at the end of a 2-h hyperglycemic clamp. The nuclear factor (NF)-kappaB (but not Oct-1) binding activity increased significantly in the hyperglycemic clamp. Western blots confirmed NF-kappaB-p65-antigen translocation into the nucleus. IkappaBalpha did not change significantly in both groups. Hyperglycemia-mediated NF-kappaB activation and increase of CML content, p21(ras), and p42/44 MAPK phosphorylation was also seen in ex vivo-isolated PBMCs stimulated with 5 or 10 mmol/l glucose. Addition of insulin did not influence the results. Inhibition of activation of ras, MAPK, or protein kinase C blocked hyperglycemia-mediated NF-kappaB activation in ex vivo-isolated PBMCs stimulated with 10 mmol/l glucose. Similar data were obtained using an NF-kappaB-luciferase reporter plasmid. Therefore, we can conclude that an acute hyperglycemia-mediated mononuclear cell activation is dependent on activation of ras, p42/p44 MAPK phosphorylation, and subsequent NF-kappaB activation and results in transcriptional activity in PBMCs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12606501     DOI: 10.2337/diabetes.52.3.621

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  42 in total

Review 1.  Targeting advanced glycation with pharmaceutical agents: where are we now?

Authors:  Danielle J Borg; Josephine M Forbes
Journal:  Glycoconj J       Date:  2016-07-09       Impact factor: 2.916

Review 2.  An immune origin of type 2 diabetes?

Authors:  H Kolb; T Mandrup-Poulsen
Journal:  Diabetologia       Date:  2005-04-30       Impact factor: 10.122

3.  Oxidative stress and glucose metabolism--is there a need to revisit effects of insulin treatment?

Authors:  P M Humpert
Journal:  Diabetologia       Date:  2010-01-06       Impact factor: 10.122

4.  Advanced glycation end products strongly activate platelets.

Authors:  Thomas Gawlowski; Bernd Stratmann; Ruth Ruetter; Christina E Buenting; Barbara Menart; Jürgen Weiss; Helen Vlassara; Theodor Koschinsky; Diethelm Tschoepe
Journal:  Eur J Nutr       Date:  2009-07-26       Impact factor: 5.614

5.  Assessment of Glucose Control Metrics by Discriminant Ratio.

Authors:  Vanessa Moscardó; Pau Herrero; Monika Reddy; Nathan R Hill; Pantelis Georgiou; Nick Oliver
Journal:  Diabetes Technol Ther       Date:  2020-10       Impact factor: 6.118

6.  Value of self-monitoring blood glucose pattern analysis in improving diabetes outcomes.

Authors:  Christopher G Parkin; Jaime A Davidson
Journal:  J Diabetes Sci Technol       Date:  2009-05-01

Review 7.  Management of critically ill patients with type 2 diabetes: The need for personalised therapy.

Authors:  Palash Kar; Karen L Jones; Michael Horowitz; Adam M Deane
Journal:  World J Diabetes       Date:  2015-06-10

8.  Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily.

Authors:  Angelika Bierhaus; Karl-Matthias Haslbeck; Per M Humpert; Birgit Liliensiek; Thomas Dehmer; Michael Morcos; Ahmed A R Sayed; Martin Andrassy; Stephan Schiekofer; Jochen G Schneider; Jörg B Schulz; Dieter Heuss; Bernhard Neundörfer; Stefan Dierl; Jochen Huber; Hans Tritschler; Ann-Marie Schmidt; Markus Schwaninger; Hans-Ulrich Haering; Erwin Schleicher; Michael Kasper; David M Stern; Bernd Arnold; Peter P Nawroth
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 9.  Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms.

Authors:  Alin Stirban; Thomas Gawlowski; Michael Roden
Journal:  Mol Metab       Date:  2013-12-07       Impact factor: 7.422

10.  Group of signs: a new method to evaluate glycemic variability.

Authors:  Francesco Zaccardi; Paola Di Stefano; Elena Busetto; Marco Orsini Federici; Andrea Manto; Fabio Infusino; Gaetano Antonio Lanza; Dario Pitocco; Giovanni Ghirlanda
Journal:  J Diabetes Sci Technol       Date:  2008-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.